Valeant Pharmaceuticals (VRX) tumbled Monday as Congressional Democrats asked to subpoena the company for documents related to drug price increases. This is the latest move in the government’s attempts to regulate the industry. Investors had their pick of worries to begin the week: the Fed’s decision to delay a hike continued to cause unease, China’s industrial profits supported fears of a slowdown, and concerns over increased regulatory scrutiny in the biotech sector pressured health care stocks. Energy Transfer Equity (ETE) was sharply lower after agreeing to acquires Williams Cos. (WMB) in a deal worth nearly $40 billion. The acquisition creates the third-largest energy franchise in North America.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.